EcoDrugPlus

Mapk Activated Protein Kinase 2

Ensembl ID : ENSDNOG00000009285
Gene Symbol: MAPKAPK2
2 Cross references
240 Possible Orthologues:

Mapk Activated Protein Kinase 5

Ensembl ID : ENSDNOG00000016827
Gene Symbol: MAPKAPK5
2 Cross references
179 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 1

Ensembl ID : ENSDNOG00000039937
Gene Symbol: MKNK1
4 Cross references
168 Possible Orthologues:

Mapk Interacting Serine/threonine Kinase 2

Ensembl ID : ENSDNOG00000049712
Gene Symbol: MKNK2
2 Cross references
225 Possible Orthologues:

Mcl1 Apoptosis Regulator, Bcl2 Family Member

Ensembl ID : ENSDNOG00000000061
Gene Symbol: MCL1
4 Cross references
245 Possible Orthologues:

Mdm2 Proto-Oncogene

Ensembl ID : ENSDNOG00000046929
Gene Symbol: MDM2
3 Cross references
215 Possible Orthologues:

Met Proto-Oncogene, Receptor Tyrosine Kinase

Ensembl ID : ENSDNOG00000039331
Gene Symbol: MET
3 Cross references
207 Possible Orthologues:

Mpl Proto-Oncogene, Thrombopoietin Receptor

Ensembl ID : ENSDNOG00000019539
Gene Symbol: MPL
2 Cross references
186 Possible Orthologues:

Mtor Associated Protein, Lst8 Homolog

Ensembl ID : ENSDNOG00000005839
Gene Symbol: MLST8
4 Cross references
203 Possible Orthologues:

Nad(P)h Quinone Dehydrogenase 1

Ensembl ID : ENSDNOG00000039902
Gene Symbol: NQO1
4 Cross references
195 Possible Orthologues:

Nadph Oxidase 4

Ensembl ID : ENSDNOG00000011906
Gene Symbol: NOX4
4 Cross references
150 Possible Orthologues:

Nfe2 Like Bzip Transcription Factor 2

Ensembl ID : ENSDNOG00000019020
Gene Symbol: NFE2L2
2 Cross references
216 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).